




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12Q 1/68, G01N 33/543, 33/58 G01N 33/571		A1	(11) International Publication Number: WO 90/06374 (43) International Publication Date: 14 June 1990 (14.06.90)
(21) International Application Number: PCT/AU89/00526 (22) International Filing Date: 8 December 1989 (08.12.89) (30) Priority data: PJ 1889 9 December 1988 (09.12.88) AU PJ 5080 4 July 1989 (04.07.89) AU (71) Applicant (for all designated States except US): AMRAD CORPORATION LIMITED [AU/AU]; 17-23 Cotham Road, Kew, VIC 3101 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only) : KEMP, David, James [AU/AU]; 309 Belmore Road, North Balwyn, VIC 3104 (AU). FOOTE, Simon, James [AU/AU]; 6 Finsbury Street, Flemington, VIC 3031 (AU). PETERSON, Michael, Gregory [AU/AU]; 9 Lowan Avenue, Lower Templestowe, VIC 3107 (AU). SAMARAS, Nicholas [AU/AU]; 1 Teak Street, Caulfield, VIC 3162 (AU). SMITH, Donald [GB/GB]; Dunglass Mill, Cocksburnpath, Berwickshire TD13 5XE (GB).		(74) Agents: SLATTERY, John, Michael et al.; Davies & Collison, 1 Little Collins Street, Melbourne, VIC 3000 (AU). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: **AMPLIFIED DNA ASSAY**

(57) Abstract

A method for capturing amplified target DNA on a solid substrate comprising incorporating a ligand into said DNA by a polymerase chain reaction using a set of primers wherein one of the primers bears the ligand, and contacting the so treated DNA with a solid substrate having a binding reagent for said ligand immobilized thereon.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

5

AMPLIFIED DNA ASSAY

10

The present invention relates generally to the capture and detection of amplified target DNA in a sample. More particularly, the present invention relates to a single or multi-step amplified DNA assay (ADA) and
15 the use thereof in the rapid capture and detection of target DNA in a sample, such as in the detection of a pathogen.

The polymerase chain reaction (PCR) system (1,2)
20 for amplifying specified segments of DNA has already proved to be of great value in experimental biology (1-8, see also Australian Patent Applications Nos. 55322/86, 55323/86, 69962/87 and 77298/87 in the name of Cetus Corporation) In the PCR procedure, a sample containing
25 the DNA of interest is repetitively cycled through three temperatures. This results successively in denaturation of the DNA, annealing of synthetic oligonucleotides at the boundaries of the sequence of interest and the extension of the oligonucleotides by the DNA polymerase
30 from Thermus aquaticus (Taq) (2). The exponentially amplified DNA segment can then be detected by simple procedures such as staining with ethidium bromide after agarose gel electrophoresis, or by hybridisation or sequencing to ensure that it is the expected sequence
35 (1-6).

The PCR system should rapidly replace conventional procedures in many areas of mass screening (7). One of these is the detection of pathogens because of the generality of the technique and its exquisite sensitivity. Testing blood samples for human immunodeficiency virus (HIV) sequences is one such area in which preliminary studies have been reported (8). Other areas include epidemiology and human genetic applications such as HLA typing and screening for genetic diseases. However, current procedures for detection of the products of PCR reactions are not well suited to mass screening as they generally require gel electrophoresis. Further, artefactual DNA molecules resulting from such events as dimerization of the primers or misincorporation of primers into irrelevant sequences can readily arise and so hybridisation or sequence information is necessary to identify a molecule with certainty. Hence, an assay system for detecting DNA amplified by the PCR procedure that is highly specific, rapid, readily applicable to mass screening, suitable for any known sequence and uses equipment already available in many laboratories would be advantageous.

The present invention relates to an amplified DNA assay enabling the capture detection of target DNA in a sample. The assay may be accomplished in one or more steps.

Accordingly, the present invention contemplates a method for capturing amplified target DNA on a solid substrate comprising incorporating a first ligand into said DNA by a polymerase chain reaction using a set of primers wherein one of the primers bears the ligand and contacting the so treated DNA with a solid substrate having a binding reagent for said ligand immobilized thereon.

The present invention further contemplates the detection of said captured DNA by contacting said immobilized amplified DNA with a detection reagent which is capable of binding to a second ligand previously
5 incorporated into said amplified DNA by the polymerase chain reaction using a set of primers wherein one of the primers bears the ligand capable of binding to a detection reagent.

10 Accordingly, the present invention contemplates a method for the detection of target DNA in a sample comprising optionally amplifying said DNA by the polymerase chain reaction and detecting a ligand or label incorporated into said DNA after said DNA has been
15 immobilized onto a solid substrate.

In one embodiment, the present method first optionally amplifies target DNA by the polymerase chain reaction procedure using a first set of oligonucleotide
20 primers selected to be complementary to the strands of said target DNA. The first PCR is optional to the extent that there may be an amount of target DNA sufficient to enable the practitioner to proceed to the next step without a first amplification. The target DNA, amplified
25 or not, is amplified by the polymerase chain reaction procedure using a second set of oligonucleotide primers, the primers of said second set being selected to be complementary to the strands of said target DNA and being nested between the primers of said first set and wherein
30 one of the primers of said second set bears a first ligand and the other of the primers of said second set bears a second ligand or a label. The amplified DNA is contacted to a solid substrate having a binding reagent for said first ligand immobilized thereon.

35

Another aspect of the present invention relates to a method for detecting target DNA, said DNA optionally

amplified by a first polymerase chain reaction using a first set of oligonucleotide primers selected to be complementary to the strands of said target DNA, said method comprising subjecting said amplified DNA to a
5 second polymerase chain reaction using a second set of oligonucleotide primers selected to be complementary to the strands of said target DNA and being nested between the primers of said first set and wherein one of the primers of said second set bears a first ligand and the
10 other of the primers of said second set bears a second ligand or a label, contacting the amplified DNA with a solid substrate having a binding reagent for said first ligand immobilized thereon and then detecting the second ligand or label to indicate the presence of amplified DNA
15 bound to said solid substrate.

Yet another aspect of the present invention is directed to a test kit for detecting target DNA in a sample by the amplified DNA assay comprising in
20 compartmental form, a first container adapted to contain the reagents for a optional polymerase chain reaction and capable of receiving said target DNA including said first and/or optionally second sets of oligonucleotide primers; a second container adapted to contain said second set of
25 oligonucleotide primers and the reagents for a second polymerase chain reaction when not carried in said first container; a solid substrate coated with a binding reagent; and a means for detecting amplified DNA bound to said solid substrate.

30

Still another aspect of the present invention relates to an amplified DNA assay for the detection of target DNA in a sample, which assay comprises the steps of:

35

- a. optionally amplifying said target DNA, if present in said sample, by the polymerase

chain reaction procedure using a first set of oligonucleotide primers selected to be complementary to the strands of said target DNA;

5

- b. amplifying or further amplifying the product of step a. by the polymerase chain reaction procedure using a second set of oligonucleotide primers, the primers of said second set being selected to be complementary to the strands of said target DNA and being nested between the primers of said first set, and wherein one of the primers of said second set bears a first ligand and the other of the primers of said second set bears a second ligand or a label;
- c. contacting the amplified product of step b. with a solid substrate having a binding reagent for said first ligand immobilised thereon; and
- d. detecting the second ligand or label to indicate the presence of amplified DNA bound to said solid substrate.

In further accordance with the present invention, steps (a) and (b) above can occur in either a single reaction mixture or two successive reaction mixtures.

In another aspect of the present invention, the target DNA may be subjected directly to one or more cycles of PCR using the labelled second set of primers and then subjected to binding to the said substrate. This would be particularly useful where there is an

abundance of target DNA and/or where the detection means is very sensitive.

The following abbreviations are used in the present specification:

	PCR	Polymerase chain reaction
	DNA	Deoxyribonucleic acid
	A	Adenine
10	T	Thymine
	G	Guanine
	C	Cytosine
	GST	Glutathione-S-transferase
	ADA	Amplified DNA assay
15	HIV	Human immunodeficiency virus
	TMB	Tetramethylbenzidine
	ABTS	2.2'-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid)
	MTPBS	Mouse tonicity phosphate buffered saline
20	RT	Room temperature
	PBS	Phosphate buffered saline

In the accompanying drawings:

Figure 1 shows the three basic steps of one embodiment of the ADA. In step 1, a DNA segment is amplified from a biological sample via oligonucleotides a and b. In step 2, specific ligands are incorporated into the amplified DNA segment through at least 3 further cycles of amplification via internally nested oligonucleotides. Oligonucleotide c. bears a molecule of biotin at its 5' terminus and oligonucleotide d. bears a 5' nucleotide sequence specifically recognised by the DNA binding protein, GCN4, of Saccharomyces cerevisiae. In step 3, ligand bearing DNA segments are bound to a solid support coated with purified GCN4 produced in bacteria (GST-GCN4) and are detected via binding of avidin-peroxidase to the

biotin of oligonucleotide c. and subsequent colorimetric detection of peroxidase activity.

Figure 2 shows the structure of yeast GCN4 and GST-GCN4.

5 At the top is the structure of the Saccharomyces cerevisiae GCN4 gene (9) with the coding region (281 amino acids) boxed and proposed transcription activation and DNA binding regions of the GCN4 protein indicated by hatching (10). Also indicated are the positions of
10 oligonucleotides 1-3 used to amplify the GCN4 gene from yeast DNA by PCR. Fig.2 also shows the structure of genes encoding GST-GCN4 fusion proteins produced in E. coli by introducing fragments of the GCN4 gene into the plasmid expression vector pGEX-2T (11). The GCN4 gene
15 was amplified from yeast DNA using oligonucleotides 2 and 3 or 1 and 3 to generate plasmids encoding partial (GST-GCN4 3.12) or full-length (GST-GCN4 6.8) versions of the GCN4 polypeptide fused to Schistosoma japonicum glutathione-S-transferase (GST).

20

Figure 3a shows fractionation by polyacrylamide gel electrophoresis of total proteins (lanes 1 and 4) from E. coli strain 7118 transfected with plasmids pGST-GCN4 3.12 (lanes 1-3) or pGST-GCN4 6.8 (lanes 4-6) and grown in the
25 presence of 0.1 mM IPTG for 1 hour at 37°C. Also shown is material purified from lysed bacteria by one-step affinity chromatography (lanes 3 and 6) and soluble proteins remaining after incubation with glutathione-agarose beads (lanes 2 and 5). Figure 3b
30 shows a gel retardation assay demonstrating that the mobility of a ^{32}P labelled DNA fragment containing a GCN4 binding site is decreased when it is mixed with purified GST-GCN4 3.12 (lanes 2 and 4) or GST-GCN4 6.8 (lane 6) in comparison to its mobility in the absence of protein
35 (lane 1).

Figure 4 shows the effect of added carrier DNA on the specificity of ADAs on DNA from HIV plasmid pHXBc2. In row A there was no added carrier DNA in the microtitre dish, while rows B, C and D contained 1µg/ml, 0.1 µg/ml and 0.01 µg/ml of sonicated human DNA, respectively. Step 1 of the ADA was for 30 cycles as described in Example 1, below, using oligonucleotides a. and b. and a SacI - SalI fragment from pHXBc2 (12). Samples (5ml) from step 1 were then amplified for a further 10 cycles using oligonucleotides c. plus b. (columns 1-3), c. plus d. (columns 4-6) or c. plus d2 (columns 7-9). Samples (5µl in 1, 4 and 7; 0.5µl in 2, 5 and 8; 0.05µl in 3, 6 and 9) were then added to wells of plates coated with purified GST-GCN4 3.12 (a) or GST-GCN4 6.8 (b). The remaining steps of the ADAs were as in Example 1.

Figure 5 shows ADAs on DNA from HIV-infected cells. Samples 1-3, human DNA (~100ng) from a Burkitt's lymphoma; samples 4-6, human DNA (~100ng) from HIV-infected cells; samples 7-9, no DNA; samples 10-12, DNA (~1ng) from plasmid pHXBc2. Step 1 of the ADA was for 35 cycles as described in Example 1 using oligonucleotides a. and b. Samples of 10µl from step 1 were then amplified a further 6 cycles using oligonucleotides c. plus d. Samples (15µl for 1, 4, 7 and 10; 3µl for 2, 5, 8 and 11; and 0.6µl for 3, 6, 9 and 12) were added to wells of plates coated with purified GST-GCN4 3.12 in the presence of sonicated human DNA (1µg/ml). The remaining steps of the ADAs were as in Example 1.

Figure 6A shows the specificity of the one step ADA reaction. Competition of unreacted biotinylated oligonucleotides with the ADA substrate in a one step binding reaction. A PCR was performed using oligonucleotides c1 and d1 (0.2µg) with 1ng of plasmid pHXBc2 in a 100µl reaction mix, cycled 24 times. The

control did not contain any plasmid DNA. For rows 1 and 3 the volumes of PCR reaction indicated were added to 50µl of binding mix (without powdered milk) containing the dilutions of a 5 mg/ml avidin-peroxidase solution indicated. For rows 2 and 4, the volumes of PCR reaction indicated were added, and a further 8µl of the control PCR was added to each well. The binding reactions and colour development are described in Example 3.

10 Figure 6B shows the specificity of the one step binding reaction. The procedure was as for Fig. 6A, except that the wells contained the % (w/v) of non-fat powdered milk indicated. The top and bottom rows contained 5µl/well of the PCR mix described above. For row 2, oligonucleotide d was omitted. For row 3, there was no DNA in the PCR. Row 4 was as for row 3, but an unrelated oligonucleotide (1µg/ml) was added. For row 5, the wells were not coated with GCN4.

20 Figure 7 shows the effect of annealing temperature on incorporation. PCRs were carried out with 1ng plasmid pHXBc2 and oligonucleotides a1 and b1 (1µg/ml), c2 and d2 (2µg/ml) as indicated, and cycled under the conditions shown, 10µl samples were fractionated on a 1.6% (w/v) agarose gel in the presence of 1µg/ml ethidium bromide. For A the concentrations of a1 and b1 were 0.3µg/ml. For B the concentrations of oligonucleotides a1 and c1 in the PCR were the following in successive tracks: a1= 6, 6, 2, 0.6, 2 µg/ml, b1= 3 µg/ml, c1= 20, 30, 10, 10, 20 µg/ml, d1= 5 µg/ml.

Figure 8A shows the sensitivity with different oligonucleotide concentrations. Two step PCRs were carried out with oligonucleotides a2 and b2 (concentrations as indicated) and c2 and d2 (5µg/ml) with the amounts of Plasmid indicated (at the right in µg) in a 20µl reaction, cycled 30 times (95°/30 sec, 65°/60 sec)

and then 12 times (95°/30 sec, 40°/60 sec, 65°/30 sec). 5µl of the product was then analysed in an ADA with a one-step binding reaction.

- 5 Figure 8B shows the sensitivity of ADA reactions. Comparison of the sensitivity of ADA reactions using a and b oligonucleotides with different spacings from c2 and d2. The a and b oligonucleotides were at 0.3µg/ml.
- 10 Figure 9 shows the ADA dependence on temperature shift. Two step PCRs were carried out with oligonucleotides a2, b2, c2 and d2 as in Fig. 3B. The DNA was from 5×10^3 HIV-infected CEM cells. The PCRs were cycled at 95°/30 sec, 65°/60 sec for the number of cycles indicated by the
- 15 arrows, and then at 95°/30 sec, 40°/60 sec, 65°/30 sec for 0, 5 and 10 further cycles. The number of cycles indicated at the bottom is the total number for each sample.
- 20 Figure 10 shows the detection of HIV in cultured cells. DNA from uninfected or HIV-infected CEM cells was used as the input DNA for PCR reactions containing oligonucleotides a2 and b2 (0.3µg/ml) and c2 (2.5µg/ml) and d2 (5µg/ml) that were cycled 30 times (95°/30 sec,
- 25 65°/60 sec) followed by a further 10 (top 3 rows in right panel) or 15 (bottom 3 rows in right panel, and left panel) cycles (95°/30 sec, 40°/60 sec, 65°/30 sec). Plasmid DNA was used as a positive control. ADA reactions with a one-step binding reaction were carried
- 30 out on 5µl samples, and agarose gel electrophoresis on 10ml samples. The DNA samples analysed in the ADAs or by gel electrophoresis represented the material obtained from the number of cells indicated, or from the number of plasmid molecules indicated.
- 35 Figure 11 shows the quantitation of the ADA reactions shown in Figure 10.

Figure 12 shows the comparison of TMB and ABTS in an ADA mediated by GCN4-coated pins.

5 Figure 13 shows a comparison of GCN4 and TyrR in an ADA reaction.

Figure 14 shows the effect of thrombin cleavage of GCN4 in the ADA.

10

Figure 15 shows the results of a clinical trial performed on Peripheral Blood Lymphocytes (PBL's) taken from patients positively diagnosed as suffering from AIDS or from negative controls. The method is as described in
15 Figure 10 except 2 PCR's, 35 and 12 cycles respectively were used. Abbreviations are defined in Example 9.

In general terms, in one embodiment of the present invention, target DNA is first amplified by PCR using a
20 first set of appropriate oligonucleotide primers in accordance with the known PCR procedure and then a second set of oligonucleotide primers, nested between the first two, are incorporated by a small number of additional cycles. The nucleotides in the second set of primers
25 bear ligands, for example, one can be biotinylated and the other contain a site for a double stranded DNA binding protein. After linking to an immobilised affinity reagent, such as a DNA binding protein and labelling with a second affinity reagent, for example
30 avidin linked to horseradish peroxidase, reaction with a chromogenic substrate allows detection of the amplified DNA. Furthermore, a system such as digoxigenin could be employed. Where there is sufficient target DNA without a first amplification or for other reason such as
35 convenience or speed of assay, the target DNA may be directly subjected to incorporation by the labelled primers.

The assay procedure of the present invention is described in detail herein with particular reference to an assay for the detection of Human Immunodeficiency Virus (HIV) sequences. It will be understood, however, that this particular assay is described by way of exemplification of the invention and the invention has wider application as discussed below. Accordingly, by "target DNA" is meant any eukaryotic, prokaryotic or viral nucleic acid sequence and includes the identification of pathogens or the screening of human or other mammalian genetic disorders such as in cancer cells. Furthermore, target DNA encompasses RNA wherein by the action of reverse transcriptase, corresponding DNA is first synthesised, i.e. cDNA copied by reverse transcriptase from RNA. Target DNA also extends, therefore, to RNA viruses. Target DNA also extends to plant genetic sequences and to their pathogens.

Furthermore, the source of target DNA may vary depending on the particular circumstances and relative convenience. For example, one embodiment of the subject invention is described in terms of detecting HIV sequences in blood. However, this is done with the understanding these and other target sequences may be isolated from other bodily fluids such as, but not limited to, saliva. Accordingly, the present invention extends to the detection of target DNA in any suitable biological fluid such as blood, saliva, lymph fluid, cell and tissue extracts, culture supernatants, plant sap and/or other fluids or tissue extracts, aerosols, various environmental locations (eg soil, water, etc.) and the like.

The ADA procedure of this invention provides a very sensitive, specific, simple and convenient method for detecting specific DNA segments amplified by at least

one PCR. The sensitivity of the method results from the combination of the inherent sensitivity of the PCR procedure itself (it can detect a single DNA molecule against a background of at least 10^6 human genomes (2)) and a sensitive novel method for detecting the amplified DNA. The data below show that molecules of the ligand-containing amplified DNA can readily be detected and only a small fraction of the product from a typical PCR reaction is necessary for detection.

10

The specificity of the procedure reflects the fact that the ADA, in one embodiment, uses two successive PCR reactions with nested oligonucleotide primers. Only DNA molecules generated in the second step are detected in the final step because the ligands are only introduced during the second step. Alternatively, the target DNA may undergo the binding step directly without need of a first PCR. This specificity may be further increased, as in Example 2 herein, by the fact that GST-GCN4 only binds to double-stranded DNA - it does not recognise the single-stranded oligonucleotides. As the second step utilises only a small number of cycles (for example 3-12 cycles), there is insufficient time for accumulation of significant amounts of primer-dimers derived from the oligonucleotides of the second set or other double stranded DNA artefacts. Furthermore, any such artefacts generated in the first PCR step, for example by spurious priming at other places in the genome, are not amplified in the second step because they will not contain the nested sequences of the second set of primers. Primer-dimers formed in the first step will not be detected as they do not contain the ligands.

It is another embodiment of the subject invention that the PCR can be performed in one reaction mixture effectively resulting in a "single step ADA". This modification to the multi-step procedure previously

outlined is predicated in part on a strong dependence of the thermal stability of an oligonucleotide duplex on its length and hence, oligonucleotide primers can be selected such that their incorporation in a PCR is critically dependent on the annealing temperature. Consequently, if one set of primers is considerably longer than a second set, then successive PCR reactions can be carried out in the one reaction mixture by incubating the mixture through first a high temperature and then a low temperature thermal cycle regime. (See Example 5).

The present invention, therefore, extends to both the multi-step and single step ADA.

The one step ADA also has advantages in the binding step where the binding of the amplified product to the binding reagent immobilized to a solid substance occurs simultaneously to the binding of or to a detection complex. In one embodiment, the amplified DNA is bound to GST-GCN4 immobilized in the wells of a microtitre dish while simultaneously binding to the avidin-peroxidase conjugate.

A further aspect of the one step ADA relates to the use of single or multiple beads or pins coated with a binding reagent to transfer the amplified product from a reaction vessel, after washing, and contacting immobilized amplified product to a detection complex, to detection substrate. For example, the amplified DNA is transferred from a microtiter well by an array of GST-GCN4-coated beads or pins and, after washing and contacting with avidin-peroxidase, the beads are immersed in a microtiter dish containing ABTS substrate.

The successive PCR reactions can be carried out in the one reaction mixture, simply by incubating the mixture through first a high temperature and then a low

temperature thermal cycle regime. As the complete PCR mixture containing all 4 oligonucleotides and enzyme (minus sample DNA) for this can be stored frozen, the protocol becomes greatly simplified, namely (1) the DNA sample is added to the PCR mixture, a drop of paraffin oil is added and the tube is placed on a thermal cycler and subjected to the two successive thermal regimes; (2) a sample is then placed in the GST-GCN4-coated microtiter well for simultaneous immobilization and binding; and (3) the dish is then washed and substrate added. This protocol is well suited to handle moderate numbers of samples. For example, the results for 50 samples can be obtained about 1 hour after completion of the PCRs.

In the one step assay, the amplified DNA binds to GST-GCN4 immobilized in the wells of a microtiter dish while simultaneously binding to the avidin-peroxidase conjugate. This decreases both the number of manipulations required and the time taken in handling samples, with no decrease in sensitivity or specificity. However, unincorporated biotinylated oligonucleotides compete with the amplified DNA for binding to avidin and it is necessary to ensure that the amount of biotin does not exceed the binding capacity of the avidin.

Furthermore, the one step assay also provides a protocol where the PCR with two successive thermal regimes is itself performed in a modified microtiter dish. The amplified DNA molecules are then bound to GCN4 immobilized on polystyrene beads attached to the lid of a microtiter dish. While this procedure cannot take advantage of the simultaneous immobilization and avidin-peroxidase binding, it has the very considerable advantage that after pipetting individual DNA samples into the first microtiter well, 96 samples can be handled simultaneously in a manner analogous to the widely used "FAST ELISA" system.

In all of these systems, streamlining of the detection systems has now reached the point where the time spent on preparing and handling individual DNA samples is the rate limiting event. The less abundant the target sequence, the higher the degree of purification that will be necessary. If the target sequence is detectable in less than 1 μ l of whole blood, then boiling the sample can be sufficient. However, if the required sensitivity demands that the total DNA from a large volume of blood is added to a single PCR, purification is required. It is self evident that this depends both in the intrinsic sensitivity of the assay (i.e., the number of relevant molecules than can be detected in an ideal situation) and the maximum amount of sample before inhibition of the system occurs. Blood seems to be a particularly bad DNA source because of the high protein content. Clearly, the minimal purification protocol necessary for a particular system is dependent on these parameters. Additionally, these modifications to the multi-step protocol described herein are capable of detecting HIV sequences against a background of human DNA.

The simplicity and convenience of the ADA results from the fact that after the PCR steps, the sample may be treated in precisely the same manner as a routine enzyme-linked immunosorbent assay (ELISA), using the same equipment. As the immobilisation by affinity binding to the solid phase (for example, GST-GCN4 or avidin) can be carried out in the same step as labelling at the other end of the DNA molecule (in the example, with avidin-peroxidase), the number of pipettings and washing is minimised. Further, if the solid phase coated with the affinity reagent consisted of pins in the roof of a microtitre dish, washing could be simplified. This latter approach also could readily lend itself to

automation of the detection steps. The reactions in the example herein are extremely rapid because of the high affinities of avidin and GCN4 for their substrates, and the high Vmax of horseradish peroxidase.

5

The ADA system described in detail herein is only one possible formulation that has many alternatives. Obviously, the approach could be used for detection of many other viral, bacterial, protozoan, fungal and mycoplasmal pathogens. Screening for hepatitis, tuberculosis, malaria and candida infections are among the obvious applications involving these disparate organisms. Similarly, this system could be used for the detection of cellular disorders such as cancers and the like. The outstandingly useful feature of the ADA approach is that it is only necessary to change the sequences of the oligonucleotides in order to detect any gene from any organism by a simple colour test. If the length of the test DNA segment for each case is the same, then the kinetics of the detection steps should be identical as the same affinity reagents are interacting with the same ligands in all cases. This contrasts with the ELISA system where the affinity and kinetics are determined by the monoclonal antibodies, which differ for each situation. Another potential application lies in determining the genotypes of certain pathogens. For example, in Plasmodium falciparum, some genes contain variable regions defining different antigenic determinants surrounded by relatively conserved regions (13). If the probes of the first set of primers corresponded to such flanking conserved regions, the products of the first PCR step could be tested with several pairs of oligonucleotides corresponding to internal variable regions that define the different serotypes. The ADA described herein is also applicable to screening for genetic diseases such as cystic fibrosis and cancers amongst others.

10

15

20

25

30

35

The ADA system of the present invention could in theory employ a wide variety of ligands and/or affinity reagents. In one embodiment, the double-stranded DNA -
5 specific DNA binding protein is of the leucine zipper type i.e. GCN4. A range of other DNA binding proteins of this type could be used, including thrombin-cleaved GCN4 (Figure 2, 14). Accordingly, the present invention extends to leucine zipper type DNA binding proteins such
10 as GCN4 and/or its derivatives which includes GST-GCN4, thrombin-cleaved GCN4 and any other modifications thereof such as additions, deletion and/or substitution to the GCN4 amino acid and/or carbohydrate moieties provided said derivatives retain DNA binding activity

15

Another DNA binding protein that could be used in the ADA is the TyrR protein of the "Helix turn Helix" type and which has a C-terminal DNA binding domain (Dr V. Argyropoulos, Thesis submitted for degree of Doctor of
20 Philosophy, The University of Melbourne, Parkville, Victoria, Australia). Other DNA binding proteins which may be used in the ADA are well known and include, for example, the "zinc finger" type. These binding proteins are reviewed by Struhl (19). Furthermore, an alternative
25 to biotin would be a simple chromophore or a fluorescent dye. In this variation, the increase in specificity that comes from the ability of such DNA binding proteins to discriminate between double stranded (i.e. incorporated) and single stranded (i.e. unincorporated)
30 oligonucleotides would be lost. This could be acceptable in many situations as there is already considerable specificity in the reactions.

As well as the applications to pathogens such as
35 HIV used to develop the system here and the applications to genotyping pathogens mentioned above, the ADA system could be used with appropriate modification for virtually

any application amenable to PCR itself (see for example references (1) to (8) and the Australian Patent Applications cited above). Major examples would include human genetics applications such as HLA typing and prenatal diagnosis of genetic disorders. The simplicity, specificity and generality of the approach should find many other applications.

Another embodiment of the subject invention employs a single PCR to incorporate directly label and/or ligand bound primers into target DNA without first being amplified and then exposing labelled target DNA to the solid support prior to, or simultaneously to, detection. This provides an even more streamlined method of detecting target DNA and makes the first PCR an optional step depending on the circumstances.

The present invention also extends to a conjugate consisting essentially of a support, a DNA binding protein and preferably a double-stranded DNA-specific DNA binding protein and more preferably GST-GCN4 or TyrR immobilized on said support and an amplified double-stranded DNA bound at a first end to said binding protein, such as to GST-GCN4. The conjugate further comprises at the second end of said double-stranded DNA, a label and preferably said label is an enzyme. In one embodiment the label is conjugated to the amplified DNA through an avidin-biotin bridge.

The present invention is further described by the following non-limiting examples.

EXAMPLE 1

MULTI-STEP ADA

Materials and methods

Isolation and expression of the GCN4 gene from S. cerevisiae.

The complete coding region of the GCN4 gene from S. cerevisiae (9) was synthesized by PCR on a crude DNA preparation using oligo 1 (GGAATTCTAATGTCCGAATATCAGCCA) and oligo 3 (GGAATTCAGCGTTCGCCAACTAATTTC) of GCN4, and incorporating EcoRI sites at their 5' termini (Fig.2a). After cleaving with EcoRI, the DNA was ligated to EcoRI cut DNA of the expression vector pGEX-2T (11). A smaller portion of GCN4 was also isolated by PCR using oligo 3 above and oligo 2 (CGGATCCATGTTTGAGTATGAAAACC) containing a BamHI site at the 5' terminus (Fig.2a) and insertion of the PCR product after cleavage with BamHI and EcoRI into BamHI and EcoRI cut pGEX-2T DNA.

Gel retardation assay

Gel retardation was carried out as described (15) on 7.5% (w/v) polyacrylamide gels except that no blocking DNA was present. The substrate for binding was made by annealing 40ng each two oligonucleotides (CCACCTAGCGGATGACTCATTTTTTTTCTTAGCG and CGCTAAGAAAAAATGAGTC) and incubating them with Taq DNA polymerase (Cetus) in a reaction mix identical to that used for PCR except that dATP was replaced by 20mCi a ³²P-dATP (Amersham). After 5 minutes at 70°C, dATP was added to 0.25mM and the incubation continued for 5 minutes. Unincorporated a ³²P-dATP was removed by passage through a Sephadex G-10 spin column.

Amplification of HIV Sequences - Step 1.

PCR reactions for amplification of p24 sequences from DNA isolated from HIV infected cells contained 50mM KCl, 10mM Tris pH 8.4, 2.5mM Cl₂, 0.25mM each dATP, dCTP, dGTP and dTTP, 0.01% gelatin, 1.5 units Taq DNA polymerase (Cetus), 4ng oligonucleotide primers a. and b. and 100ng purified DNA. Reaction mixes (100ml) were cycled approximately 30 times between 40°C, 70°C and 95°C for 1.5, 2.0 and 1.5 minutes respectively.

Incorporation of Ligands - Step 2.

One-tenth of a Step 1 PCR reaction was subjected to at least 3 additional cycles of PCR under identical conditions except that the primers used were oligonucleotides b. and c., c. and d. or c. and d1.

5 Sequence of Oligonucleotides

The sequences (12) of the oligonucleotides corresponding to the p24 gene of HIV used were:

- a. AGAGAACCAAGGGGAAGTGA (positions 1481-1500).
- 10 b. TCTCTAAAGGGTTCCTTTGG (positions 1661-1680)
- c. CATAGCAGGAAGTACTAGTA (positions 1501-1520).
Oligonucleotide c. was biotinylated at the 5' end.
- d. AAGTGACTCAAGTGACTCAA/TCCTTGTCTTATGTCCAGAA
(nucleotides 5' to the slash correspond to an
15 artificial GCN4 binding site (14), while those 3' to the slash correspond to positions 1641-1660).
- d1. AGCGGATGACTCATTTTTTTT/TCCTTGTCTTATGTCCAGAA
(nucleotides 5' to the slash correspond to an
artificial GCN4 binding site (14), while those 3'
20 to the slash correspond to positions 1641-1660).

Preparation of DNA from HIV-infected cells.

- CEM cells were derived by culturing human
25 peripheral blood cells from a patient with acute lymphoblastic leukaemia, and then infected with HTLV IIIb. DNA was purified using guanidine HCl and CsCl centrifugation.

Detection of Amplified DNA - Step 3.

- 30 Microtiter trays (Dynatech Laboratories Inc.) were coated with purified GST-GCN4 fusion polypeptides at approximately 1µg/ml in mouse tonicity phosphate-buffered saline (MTPBS) for 3 hours at 37°C (50µl per well) and then blocked with 1% (w/v) bovine serum albumin (fraction
35 V) (Flow Laboratories) in MTPBS for 1 hour at 37°C. Trays were then washed with MTPBS containing 0.05% (v/v) Tween-20 (MTPBS-Tw-20) and twice with MTPBS alone, before

incubation at 20°C for 30 minutes with 50µl of ligand bearing DNA diluted in MTPBS-Tw-20. Trays were washed as before and incubated again at 20°C for 30 minutes with 50µl horseradish peroxidase -avidin D conjugate (Vector Laboratories, Inc.) at a concentration of 2.5µg/ml in MTPBS-Tw-20. After washing once in MTPBS-Tw-20 and four times in MTPBS, 100µl of fresh 0.1 M citrate pH 4.2 containing 1mM 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) and 0.1% hydrogen peroxide were added to each well and absorbance read in a Titertek Multiskan MCC/340 scanner using filters of 414nm and 492nm.

EXAMPLE 2

Results of Multi-Step ADA

15

a. The three basic steps of the ADA.

The approach to the detection of specifically amplified DNA is outlined in Figure 1. The ADA consists of three basic steps, the first two of which are different PCR reactions performed successively. A sample of the amplified DNA is then placed in a well of a microtitre dish for detection. As described above, there are many different possible permutations of the ADA of varying specificity and simplicity. For the sake of clarity, only one example of the theoretically most specific formulation is described in this section.

20

Step 1: Amplification.

This step is simply a standard PCR reaction performed on any suitable DNA-containing extract relevant to the sequence of interest, for a large number of cycles. The oligonucleotides for step 1 (designated a and b in Figure 1) are limiting for this reaction. Step 1 simply amplifies the desired segment of DNA.

30

Step 2: Sequence-specific ligand incorporation.

35

This step achieves specificity and simultaneously incorporates ligands into the PCR products that can react with affinity reagents, and thereby be detected in step

3. For step 2, two new oligonucleotides (designated c and d in Fig.1) are used for a second PCR reaction that can be cycled for as little as three cycles. This achieves specificity because oligonucleotides c and d are nested between oligonucleotides a and b. There are only a small number of cycles and therefore the only molecules that will form to a detectable extent are those generated by amplification of the correct sequence in step 1. Step 2 also incorporates the ligands. This can be done either as shown for oligonucleotide c, which is biotinylated, or as shown for oligonucleotide d which contains extra sequences encoding the recognition site for a double-stranded DNA binding protein, such as the yeast regulatory protein GCN4 (14). At least three cycles of step 2 are necessary to generate blunt-ended molecules with these ligands at both ends (Fig.1).

Step 3: Anchoring and enzyme-linked-labelling of the amplified DNA by affinity binding.

This step attaches the amplified DNA to a solid phase by affinity binding at one end, and is followed after washing by attachment of an enzyme by affinity binding at the other end for subsequent colour generation. For step 3, a sample from step 2 is added to a well of a microtitre dish. The well has been pre-coated with one of the affinity reagents, for example a cloned fused polypeptide bearing DNA binding protein GCN4 (see below). This polypeptide specifically immobilises the amplified molecules because of its affinity for double stranded DNA containing the correct sequence, incorporated via oligonucleotide d. After washing, a solution of the other affinity reagent conjugated to an enzyme, for example avidin linked to horseradish peroxidase, is added. This binds to the biotin linked to oligonucleotide c. As is evident, the locations of the two affinity reagents could readily be swapped (see below).

After washing, a chromogenic substrate is added to the microtitre dish, allowed to develop and the absorbance is read in a microtitre-plate reader.

5 **b. Generation of a DNA binding protein that can be readily purified.**

In order to generate large amounts of a high-affinity DNA binding protein suitable for routine use in the ADA, the Saccharomyces cerevisiae regulatory protein GCN4 has been expressed as a glutathione-S-transferase (GST) fusion protein as shown in Figure 2. Plasmid pGST-GCN4-3.12 contains most of the sequence of GCN4 from Saccharomyces cerevisiae, including the C-terminal DNA-binding region, inserted into the plasmid pGEX-2T (11), while the plasmid pGST-GCN4-6.8 contains the entire coding sequence of GCN4. At the N-terminus, the GST-GCN4 fused polypeptide contains the entire sequence of glutathione-S-transferase (GST) from Schistosoma japonicum, which allows purification of the molecule in one simple affinity step by binding to glutathione-agarose beads (11). Figure 3 shows that the GST-GCN4 polypeptides are abundant in Escherichia coli clones transformed with these plasmids. After one-step affinity purification, each of the GST-GCN4 polypeptides was detected as two Coomassie-blue stained bands after polyacrylamide gel electrophoresis (Fig.3a). These purified proteins retain the ability to bind to the consensus GCN4 binding sequence as revealed by a gel retardation assay (Fig.3b).

30 Hence both of the necessary affinity reagents (GST-GCN4 and avidin) are now readily available. Further, each of them can be used in an ADA test either to anchor the PCR-amplified DNA to the solid phase or to label the DNA in the aqueous phase (see below).

35

c. Application of the ADA to a DNA segment encoding a Human Immunodeficiency Virus (HIV) sequence.

Because of the important clinical implications a region of the HIV genome was chosen as test sequence. Oligonucleotides corresponding in position to those labelled a, b, c and d in Fig.1 were synthesised for the p24 gene of HIV and are defined in Materials and Methods. To develop the ADA, plasmid pHXBc2 bearing this gene was used initially as the test source. In initial studies to establish that the affinity reactions were feasible, DNA molecules with a biotin ligand at one end and a GCN4 binding site at the other were generated by PCR amplification of the plasmid with oligonucleotides a. and b. followed by amplification with oligonucleotides c and d. After binding these products to a microtitre well precoated with GST-GCN4 followed by washing and binding of avidin linked to peroxidase, and then washing and reaction with the chromogenic substrate, an intense reaction was observed (Fig.4). This was not observed when the PCR was carried out in the absence of plasmid DNA (Fig.5, samples 7-9).

When the amplified DNA was added to the microtitre dish in the absence of carrier DNA, the GST-GCN4 was found to bind to double-stranded DNA independently of a GCN4 binding sequence. This can be seen in row A in Fig.4 where oligonucleotides b. and c. (which both lack a GCN4 binding site) were used in the second step. However, this product formed with oligonucleotides b. and c. did not bind in the presence of carrier DNA (row B in Fig.4, columns 1-3) whereas the corresponding products formed with oligonucleotides c. and d. (row B in Fig.4, columns 4-6) or c. and d2 (row B in Fig.4, columns 7-9) still bound, as indicated by the strong reaction, although this signal is lower than in row A. Intermediate levels of carrier DNA partially competed (rows C and D). It seems that GST-GCN4 3.12 and 6.8 have similar activities and specificities.

d. Application of the ADA to human cells infected with HIV.

To examine whether the ADA could detect HIV sequences specifically in DNA from infected human cells, purified DNA from persistently infected cells was used. With DNA from uninfected cells, there was no detectable signal (Fig.5, samples 1-3) while a strong signal was obtained with DNA containing HIV (Fig.5, samples 4-6).

10

EXAMPLE 3

Single Step ADA

Materials and Methods

GST-GCN4

The fused polypeptide from clone GST-GCN4 3.12 (16) was purified by binding to glutathione-agarose as described (11).

TyrR

TyrR a DNA binding protein of the "Helix turn Helix" type, and which has a C-terminal DNA binding domain was provided for testing by Dr V. Argyropoulos (18).

25 PCR reactions

PCR reactions for amplification of p24 sequences of HIV contained 50mM KCl, 10mM Tris pH 8.4, 2.5mM MgCl₂, 0.25mM each dNTP, Taq polymerase (0.5 unit) and oligonucleotide primers at various concentrations.

30 Reaction mixes (20µl) were incubated under paraffin oil using the conditions described below. For routine use, the PCR mixes containing all components except DNA were stored as frozen aliquots.

35 Amplified DNA assays

1) One step binding assays: Microtiter trays (Dynatech Laboratories Inc.) were coated with purified

GST-GCN4 fusion polypeptides at approximately 5µg/ml of the active product(s) in phosphate buffered saline (PBS) for 1 hr at 37°C, washed 1X and then blocked with 10% (w/v) non-fat powdered milk in PBS. The plates were then
5 drained, but not washed, and 50µl/well of a mixture containing 10% (w/v) non-fat powdered milk in PBS, 4µg/ml sonicated salmon DNA, 0.05% (v/v) Tween-20 and 50µg/ml horseradish peroxidase-avidin D conjugate (Vector Laboratories Inc.) in PBS was added. Samples of the PCR
10 reactions (1-10µl) were then added and allowed to react for at least 20 min at RT. Trays were washed with MTPBS-Tween-20 four times, with MTPBS four times, with H₂O once, drained and then 100ml of fresh 0.1M Na citrate, pH 4.2, containing 1mM 2,2'-azino-bis
15 (3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) and 0.1% (v/v) hydrogen peroxide were added to each well and absorbance read in a Titertek Multiskan MCC/340 scanner on mode 2 using filters of 414nm and 492nm.

ii) ADAs with GST-GCN4 immobilized on beads.

20 The beads on the lid of a "FAST ELISA" dish (Falcon plastics) with the corners cut off were coated with GST-GCN4 by placing them in 50µl aliquots of GST-GCN4-PBS in a microtiter tray (Dynatech Laboratories Inc.) as above for 1 hr at 37°C, and then blocked in a solution
25 containing 10% (w/v) non-fat powdered milk, 4µg/ml salmon DNA and 0.05% (v/v) Tween-20 in MTPBS. The lid was then flicked to drain off excess solution and the beads placed in the microtiter dish containing the PCR samples. After 20 min at RT, the beads were washed with PBS-0.05% (v/v)
30 Tween 20. They were then reacted with 10µg/ml peroxidase-avidin conjugate in 10% (w/v) powdered milk, 0.05% (v/v) Tween-20 in MTPBS for 20 min. They were then washed extensively with PBS and reacted with ABTS as above. Alternatively, they were reacted with 0.4mM
35 Tetramethylbenzidine (TMB) in 0.1M NaAc, pH 5.5 plus 1.41mM hydrogen peroxide and read in a Titertek Multiskan MCC/340 scanner on mode 1 using filter number 7.

Oligonucleotides

Consensus oligonucleotides corresponding to sequences from the gag gene of HIV were selected after
5 aligning available sequences from the HIV database. The oligonucleotides synthesized were:

- a1 ATGAGAGAACCAAGGGGAAG
(1470->1489)
- 10 a2 GGGGGACATCAAGCAGCCATGCAAATG
(1362->1388)
- b1 TTGGTCCTTGTCTTATGTCCAGAATGC
(1656<-1630)
- b2 ACTCCCTGACATGCTGTCATCATTTCTTC
15 (1846<-1818)
- c1 5'Biotin-CATAGCAGGAACTACTAGTA
(1493->1512)
- c2 5'Biotin-CAGGAACTACTAGTA
(1498->1512)
- 20 d1 AAGTGACTCAAGTGACTCAATCCTTGTCTTATGTCCAGAA
(1652<-1633)
- d2 GGATGACTCATAGGGCTATACATTC
(1625<-1611)

25 **DNA from HIV-infected cells**

CEM cells were derived by culturing human peripheral blood cells from a patient with acute lymphoblastic leukaemia, and then infected with HIV isolate HTLV IIIb. DNA was purified using guanidine HCl
30 and CsCl centrifugation.

DNA from clinical blood samples

DNA was purified from peripheral blood leucocytes using guanidine HCl and phenol/chloroform/ethanol
35 centrifugation.

Plasmid DNA

Plasmid pHXBc2 (12) encoding the GAG gene of HIV was used as a source of DNA for developing the reactions. Generally, 1µl of a 1µg/ml solution per 1000ml of PCR was used.

5

EXAMPLE 4

A one-step binding reaction for the ADA

In the ADA described in Examples 1 and 2, the amplified DNA was first captured on GST-GCN4 immobilized in a microtiter well, the unincorporated substrates washed away and then avidin-peroxidase bound to the amplified DNA molecules. To simplify the procedure the amplified DNA was mixed with the avidin-peroxidase conjugate in the presence of protein and DNA carriers and these were bound to the immobilized GST-GCN4 in a single reaction mixture. Experiments with increasing amounts of the PCR sample and with PCR mix without DNA template showed that unincorporated biotinylated oligonucleotide rapidly competed out binding, as measured by the subsequent colour development after washing away the conjugate and adding substrate (Fig 6A). By increasing the concentration of avidin and decreasing the amount of biotin, this effect could readily be overcome. However, the increased level of peroxidase raised the background. This could be prevented by blocking protein binding sites with high levels of protein carrier, for example 10% (w/v) powdered milk, after coating the wells with GST-GCN4 (Fig 6B). Control experiments showed that it was essential to have GST-GCN4 on the plate and an appropriate target sequence on the amplified DNA (Fig 6B).

35

EXAMPLE 5

Thermal separation of the two PCR steps

Because there is a very strong dependence of the thermal stability of an oligonucleotide duplex on its

length, it was anticipated that it would be possible to choose lengths for oligonucleotides a, b, c and d (see page 26) such that their incorporation in a PCR would be critically dependent on the annealing temperature. If
5 oligonucleotides a and b are considerably longer than c and d so that they form duplexes that are considerably more stable than those of c and d, then annealing at a sufficiently high temperature should prevent
10 incorporation of c and d, allowing separation of the reactions in a mixture containing all four oligonucleotides. Preliminary studies showed unexpectedly that when different oligonucleotides 18-20 bases long were used, annealing temperatures as high as 70°C did not prevent incorporation, although the
15 efficiency was reduced. However, when c and that part of d complementary to the HIV sequence were 15 bases long, a clear thermal separation could be obtained at 65°C.

Hence, with a thermal cycling regime of only two
20 steps per cycle, 95°C for 1 min followed by 65°C for 2 min (termed "without annealing") oligonucleotides a1 and b1 (20 and 28 bases long respectively) were incorporated in 24 cycles using 1ng of plasmid DNA as the template but there was no incorporation of c2 and d2 (Fig 7A, left
25 panel) even with this high template input. If an annealing step of 40°C for 1 min was introduced ("with annealing") as well as the other 2 steps, c2 and d2 could be efficiently incorporated in an additional 24 cycles (Fig 7A, left panel). Similarly, with a total of 24
30 cycles all with annealing c and d were efficiently incorporated (Fig 7A, right panel). With annealing incorporation of a1 and b1 was less efficient (Fig 7A, right panel).

35 When all four oligonucleotides were included (Fig 7A & B), only a1 and b1 were incorporated when cycled without annealing as expected. Surprisingly, however,

with annealing the expected c2-d2 product was not obtained. Instead, a longer product corresponding to either a1-d2 and/or c2-b1 was obtained. Hence, it appears that either c2 or d2 or both are competed out by
5 a1 and/or b1. In the absence of c2, this product was obtained, but in the absence of d2, it was not indicating that it is an a1-d2 product (Fig 7A, right panel). Accordingly, the effect of lowering the relative amounts of a1 and b1 to c2 and d2 was investigated. Figure 7B
10 shows that when the amounts of a1 and b1 were decreased sufficiently, the expected c2-d2 product could indeed be obtained when cycled with annealing. As expected, only the a1-b1 product was formed without annealing, and the amounts of this were not greatly affected by lowering the
15 concentrations of a1 and b1 (Fig 7B, left panel).

ADAs on the products of these reactions were also performed (data not shown). In order for the amplified
DNA to function in such an assay, it must contain a
20 biotin moiety at one end and a GCN4 binding site at the other end. Only those reaction mixtures containing the short c-d product gave a significant colour reaction in the ADAs, confirming the structure of these molecules.

25 It is concluded that it is possible to separate PCR steps 1 and 2 thermally by choosing oligonucleotides of appropriate length. The products of the second reaction act as substrates in ADAs as expected. However, there is a competition effect that can readily eliminate
30 the reaction if the concentrations of oligonucleotides a and b are not carefully controlled.

Studies with a series of dilutions of the HIV plasmid, cycled for various times under the two different
35 temperature regimes revealed some further features of the reactions. First, it was clear that the colour intensity depended on the number of cycles both with and without

annealing. However, under these conditions the sensitivity is limited: at least 10^4 molecules are required (Example 6 below). Nevertheless, it is sensitive enough to detect HIV sequences in human DNA from persistently infected cells while the uninfected control was negative.

EXAMPLE 6

Thermal separation of the two PCRS, using more widely spaced oligonucleotides.

The apparent competition of the a and b oligonucleotides with the c and d oligonucleotides (Example 5) could result in part from steric hindrance and from kinetic effects related to the rates of annealing of the oligonucleotides. It has been noted previously (16) that this may be exacerbated by close spacing of a/c and b/d. Alternatively, c and d oligonucleotides that anneal to and are extended on the a-b template could subsequently be removed by nick translation after a second initiation event with an a or b oligonucleotide on the same template molecule in the same extension cycle. It is now clear that Tag polymerase has a 5'→3' exonuclease activity and so it can translate nicks. These effects should all be lowered if the spacing of oligonucleotides a/c and b/d are increased. Accordingly, oligonucleotides a2 and b2 were synthesized corresponding to conserved positions considerably further away from c2 and d2 than are a1 and b1.

After cycling first without and then with annealing, incorporation of oligonucleotides c2 and d2 was dependent on the concentration of oligonucleotides a2 and b2 (Fig 8a). At the optimal concentrations of a2 and b2, the c2-d2 product could be detected either by an ADA reaction or by EtBr staining from about 100 fold less input plasmid DNA than with oligonucleotides a1 and b1

(Fig 8b). Production of the c2-d2 product and colour intensity in an ADA was dependent on the number of cycles both without and with annealing and there was no significant c2-d2 product without annealing, even after 40 cycles (Fig 9).

Under these conditions, HIV sequences could be detected in the DNA obtained from about 250 cells from an HIV-infected CEM culture while there was no significant background even with 100-fold more DNA from uninfected cells (Figs 10 and 11). It can be seen on the gel shown in Fig 10 that the two successive reactions with nested oligonucleotides are indeed vital to the specificity - there are many bands generated from uninfected DNA, but these do not register as positive in the ADA.

Hence, the use of a and b oligonucleotides located further out from c and d considerably increased the sensitivity with no loss of specificity.

EXAMPLE 7**Development of a system for assaying PCR reactions
performed in microtiter dishes**

5

One way to further simplify the ADA system is to perform the PCRs in a microtiter dish and then to capture and transfer the amplified DNA from each of the 96 wells to a second dish using an array of GST-GCN4-coated beads or pins. To test whether this was feasible, 1-10 μ l samples of a PCR reaction performed with oligonucleotides c2 and d2 were made up to 20 μ l in a microtiter dish and covered with a drop of paraffin oil. The beads of a FAST ELISA screening plate were coated with GST-GCN4, blocked with powdered milk-DNA and then immersed in the PCR samples for 20 min. Subsequently the beads were washed, exposed to avidin-peroxidase, washed and placed in a microtiter dish containing ABTS substrate. The responses obtained were proportional to the amount of amplified DNA (Fig 12), and there was negligible background from equal amounts of a PCR mix incubated without substrate DNA. The colour intensity was lower by a factor of 2-3 than reactions performed using GST-GCN4-coated wells with the same material (data not shown) reflecting the lower surface area of beads. However, the sensitivity could be increased approximately 10-fold using TMB as the substrate, without any significant increase in background (Fig 12). Hence, amplified DNA molecules can be captured and transferred efficiently using GCN4 coated beads. This is surprising given that the coated beads were first dipped through a layer of paraffin oil, mimicking the conditions necessary for a PCR.

To establish that PCR reactions could be performed in a microtiter dish and then transferred as above, reactions with oligonucleotides a1 and b1, c2 and d2 or all four oligonucleotides were set up as for Fig 2 and

incubated in the wells of a flexible microtiter dish mounted on a hollow aluminum block through which water at the appropriate temperature was circulated. The top of the block was milled to fit the bottom of the dish and zinc oxide heat-sink cream was used to ensure thermal contact. Evaporation was prevented by a drop of paraffin oil. After 24 cycles with a 40°C annealing step, oligonucleotides a1-b1 and c2-d2 were incorporated into products of the expected size. Furthermore, the c2-d2 product gave an ADA reaction as expected (data not shown).

EXAMPLE 8

Use of another DNA binding protein, TyrR and thrombin-cleaved GCN4 in the ADA

15

It would be useful for some purposes to have other DNA binding proteins, with different DNA recognition sequences, that could work in an ADA reaction. For example, a set of HIV-oligonucleotides with a GST-GCN4 site could be included in the same mix as a set of hepatitis B viral oligonucleotides marked with a second DNA binding protein site, so each could be read specifically from the one PCR. TyrR is a DNA binding protein of the "Helix turn Helix" type, and which has a C-terminal DNA binding domain was provided for testing by Dr V. Argyropoulos (18).

An oligonucleotide probe was manufactured which contained a TyrR recognition site and a HIV sequence, i.e. corresponding to the oligo "d" described in Example 3 except that the TyrR recognition site replaced the GCN4 binding site.

The probe was of the sequence

35 5' TGTGTAAATATATATTTACACA/AGGGCTATACATTC
TyrR recognition site HIV oligo

This probe was incorporated into the ADA test with the oligo "c" and reaction products tested on plates coated with GST-GCN4 or TyrR.

5

Results were compared with those of the same experiment but using the original oligo "d" containing the GST-GCN4 binding site as shown in Figure 13.

10

EXAMPLE 9

Clinical Trial

The following example shows the results of a clinical trial performed on Peripheral Blood Lymphocytes (PBL's) taken from patients positively diagnosed as suffering from AIDS or from negative controls. The trial was performed blind.

20

The PBL's were prepared from blood samples by lysis in Guanidine thiocyanate buffer (4M) and centrifugation.

25

DNA was extracted and purified from PBL's using the same technique of guanidine thiocyanate centrifugation.

30

One step ADA reactions were performed using oligos a2, b2, c2 and d2 as described in Example 3.

The legend for the results provided in Figure 15 is as follows:

-	No DNA
DO	Human DNA (negative control)
CC	Positive control using CEM cells
5	transfected with HIV
CP	Positive control using Plasmid DNA
+	Positive control using CEM cells having
	Plasmid DNA incorporated therein.
20-55	Clinical specimens

10

Samples 20 and 46 were obtained from healthy humans.

The results clearly show the sensitivity and specificity of the ADA to detect HIV.

15

EXAMPLE 10

Detection of Mycoplasma pneumoniae using the ADA

20 This example shows that the ADA can be used to detect DNA from M. pneumoniae, a pathogen which can cause severe respiratory tract infections. The first experiment used plasmid DNA containing the P1 gene of M. pneumoniae as described in Hu et al, Gene, 64,217, and
25 one pair of ADA primers. The second experiment used clinical specimens (nasopharyngeal aspirate) to which had been added whole M. pneumoniae cells, and two nested pairs of primers.

30 (1) This experiment used only one pair of ADA primers, one of them being biotinylated, and the other containing the GCN4 recognition sequence, as follows:

ADA primer 1: 5'biotinyl - TCAAAACAACGACAC-3'
35 (corresponding to nucleotides 3863-3877 of the P1 gene)

ADA primer 2: 5'-GGATGACTCATTTTCAGAAAGTCGAC-3'
(corresponding to nucleotides 4144-4100 of the P1 gene;
the first 10 nucleotides constitute the GCN4 site)

5

The ADA consisted of taking purified P1 plasmid DNA and adding 0.6 μ molar/120ng of each of ADA primers 1 and 2. The first 5 cycles of amplification were conducted as follows: 94°C - 1 minute (melting); 37°C - 2 minutes (annealing); 60°C - 3 minutes (extension). The next 25 cycles were: 90°C - 1 minute; 37°C - 2 minutes; 60°C - 3 minutes; with the final extension at 72°C for 10 minutes.

15 Approximately 1/5 of the product was then analysed in a one step binding reaction in which microtitre plates were coated with GST-GCN4 (250ng/well in PBS) overnight at 4°C. Detection of amplified DNA was performed as previously described. In the second part of this
20 experiment, a smaller (i.e. 1/10) amount of DNA was used as starting material.

The mixture used for performing the PCR was:
2 units Taq polymerase (Cetus),
25 10mM Tris HCl pH 8.3,
50mM KCl,
1.5mM MgCl₂,
0.2% μ molar dNTP's,
plus ADA primers as above, in a volume of 50 μ l.

30

(ii) This experiment used 2 pairs of primers - the ADA primers described above and another pair, the PCR primers, which lie outside the ADA primers, as follows:

35

PCR primer 1: 5'-CAAGCCAAACACGAGCTCCGGCC-3'
(corresponding to nucleotides 3666-3688 of the P1 gene)

PCR primer 2: 5'-CCAGTGTCTAGCTGTTTGTCTTCCCC-3'
(corresponding to nucleotides 4208-4183 of the P1 gene)

5 Various amounts of whole M. pneumoniae cells were
added to nasopharyngeal aspirate and the amount of cells
added measured as the approximate number of genomes. The
material was centrifuged and the precipitate collected.
This was treated with proteinase K (30µl, 200 µg/ml in
10 10mM Tris CL pH 8.3) at 37°C/1 hour to free the DNA, then
at 95°C/15 minutes to inactivate the proteinase K. The
ADA was then conducted as described below.

15 The PCR mixture used was as for experiment (i),
except that it included 250ng of each ADA primer and 5ng
of each PCR primer.

20 The first round of cycling (i.e. that which
favoured the PCR primers) comprised 30 cycles as follows:
94°C - 1 minute; 65°C - 2 minutes; 72°C - 3 minutes. The
second round, for the ADA primers, comprised 15 cycles as
follows: 90°C - 1 minute; 40°C - 1 minute; 60°C - 3
minutes; followed by a final extension step at the end of
72°C for 10 minutes.

25

Analysis and detection of the amplified DNA was
performed in the same manner as in experiment (i)..

(iii) The results obtained in experiments (i) and (ii) are set out in the following tables (in which the results are scored using a plus(+) scale, with maximum colour being ++++ and no colour being -):

Experiment (i)

10	Amount of plasmid DNA	Result
	56ng (7×10^8 molecules) P1 plasmid:	++
	5.6ng (6×10^7 molecules) P1 plasmid:	+
	No plasmid control	-
15		

Experiment (ii)

20	Approx no. of <u>M. pneumoniae</u> genomes	Result
	5×10^8	+++
	2.5×10^8	+
	10^8	++
25	10^7	+/-
	5×10^5	-
	2.5×10^5	-
	10^5	-
	10^4	-
30	0	-

REFERENCES:

1. Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A. and Arnheim, N. (1985) Science 230, 1350-1354.
2. Saiki, R.K., Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B. and Erlich, H.A. (1987) Science 239, 487-491.
3. Lee, C.C., Wu, X., Gibbs, R.A., Cook, R.G., Muzny, D.M. and Caskey, C.T. (1988) Science 239, 1288-1291.
4. Gyllensten, U.B. and Erlich, H.A. (1988) Proc. Natl. Acad. Sci. USA 85, 7652-7656.
5. Triglia, T., Peterson, M.G. and Kemp, D.J. (1988) Nuc. Acids Res. 16, 8186.
6. Kim, H-S. and Smithies, O. (1988) Nuc. Acids Res. 16, 8887-8904.
7. Landegren, U., Kaiser, R., Caskey, C.T. and Hood, L. (1988) Science 242, 229-237.
8. Laure, F., Rouziox, C., Veber, F., Jacomet, C., Courgnaud, G., Blanche, S., Burgard, M., Griscelli, C. and Brechot, C. (1988) The Lancet, 538-541.
9. Hinnebusch, A.G. (1984) Proc. Natl. Acad. Sci. USA 81, 6442-6446.
10. Hope, I.A. and Struhl, K. (1986) Cell 46, 885-894.

11. Smith, D.B. and Johnson, K.S. (1988) Gene 67, 31-40.
12. Sodroski, J., Patarca, R., Rosen, C., Weng-Staah, F. and Haseltine, W. (1985) Science 229, 74-77; Sanchez-Pescadon, R., Power, M.D., Barr, P.J., Steinmer, K.S., Stemplen, M.M., Brown-Shimer, S.L., Gee, W.W., Renard, A., Randolph, A., Levy, I.A., Dina, D. and Luciw, P.A. (1985) Science 227, 484-492.
13. Kemp, D.J., Coppel, R.L. and Anders, R.F. (1987) Ann. Rev. Microbiol. 41, 181-208.
14. Hill, D.E., Hope, I.A., Macke, J.P. and Struhl, K. (1986) Science 234, 451-457.
15. Hope, I.A. and Struhl, K. (1985) Cell 43, 177-188.
16. Kemp, D.J., Smith, D.B. Foote, S.J., Samaras, N. and Peterson, M.G. (1989). Proc. Natl. Acad. Sci. USA 86, 2423-2427
17. Hinnebusch, A.G. (1984) Proc. Natl. Acad. Sci. USA 81, 6442-6446.
18. Argyropoulos, V. (1989) Thesis for Doctor of Philosophy, The University of Melbourne, Parkville, Victoria, Australia.
19. Struhl K. (1989) Trends in Biological Sciences, 14, 137.

CLAIMS:

1. A method for capturing amplified target DNA on a solid substrate comprising incorporating a first ligand into said DNA by a polymerase chain reaction using a set of primers wherein one of the primers bears the ligand and contacting the so treated DNA with a solid substrate having a binding reagent for said ligand immobilized thereon.
2. The method according to claim 1 wherein the binding reagent is a DNA binding protein.
3. The method according to claim 2 wherein the DNA binding protein is a double stranded DNA-specific DNA binding protein.
4. The method according to claim 3 wherein the double stranded DNA-specific DNA binding protein is of the leucine zipper type.
5. The method according to claim 4 wherein the DNA binding protein is GCN4 and/or its derivatives.
6. The method according to claim 5 wherein the DNA binding protein is GST-GCN4.
7. The method according to claim 5 wherein the double stranded DNA-specific DNA binding protein is of the helix turn helix type.
8. The method according to claim 7 wherein the DNA binding protein is TyrR.
9. The method according to any one of claims 1 to 8 wherein the target DNA is HIV DNA.

10. The method according to anyone of the preceding claims further comprising the detection of said captured DNA by contacting said immobilized amplified DNA with a detection reagent which is capable of binding to a second ligand incorporated into said amplified DNA by the polymerase chain reaction using a set of primers wherein one of the primers bears the ligand capable of binding to a detection reagent.

11. The method according to claim 10 wherein the second ligand is biotin.

12. The method according to claim 11 wherein the detection reagent is avidin/peroxidase.

13. The method according to any one of the preceding claims wherein the target DNA is amplified by a first polymerase chain reaction prior to the polymerase chain reaction required to incorporate the ligands.

14. A method for the detection of target DNA in a sample which comprises: optionally amplifying said target DNA, if present in said sample, by the polymerase chain reaction procedure using a first set of oligonucleotide primers selected to be complementary to the strands of said target DNA; further amplifying the amplified or non-amplified DNA by the polymerase chain reaction procedure using a second set of oligonucleotide primers, the primers of said second set being selected to be complementary to the strands of said target DNA and being nested between the primers of said first set, and wherein one of the primers of said second set bears a first ligand and the other of the primers of said second set bears a second ligand or a label; contacting the amplified DNA with a solid substrate having a binding reagent for said first ligand immobilised thereon; and

detecting the second ligand or label to indicate the presence of amplified DNA bound to said solid substrate.

15. The method according to claim 14 wherein the first and second set of oligonucleotide primers occur in a single reaction mixture.

16. The method according to claim 14 wherein the binding of the amplified DNA to the solid substance occurs simultaneously to the binding to a detection complex.

17. The method according to claim 14 wherein the target DNA is subjected directly to ligand and/or label incorporation without a first polymerase chain reaction.

18. The method according to claim 14 wherein the binding reagent is a DNA binding protein.

19. The method according to claim 18 wherein the DNA binding protein is a double stranded DNA-specific DNA binding protein.

20. The method according to claim 19 wherein the double stranded DNA-specific DNA binding protein is of the leucine zipper type.

21. The method according to claim 20 wherein the DNA binding protein is GCN4 and/or its derivatives.

22. The method according to claim 21 wherein the DNA binding protein is GST-GCN4.

23. The method according to claim 19 wherein the double stranded DNA-specific DNA binding protein is of the helix turn helix type.

24. The method according to claim 23 wherein the DNA binding protein is TyrR.

25. The method according to any one of claims 14 to 24 wherein the bound DNA is detected using a detection reagent comprising avidin/peroxidase.

26. The method according to claim 25 wherein the binding moiety for the detection reagent is biotin.

27. The method according to claim 14 wherein the target DNA is HIV DNA.

28. A method for detecting amplified target DNA, said DNA optionally amplified by a first polymerase chain reaction using a first set of oligonucleotide primers selected to be complementary to the strands of said target DNA, said method comprising subjecting said amplified or non-amplified DNA to a second polymerase chain reaction using a second set of oligonucleotide primers selected to be complementary to the strands of said target DNA and being nested between the primers of said first set and wherein one of the primers of said second set bears a first ligand and the other of the primers of said second set bears a second ligand or a label, contacting the amplified DNA with a solid substrate having a binding reagent for said first ligand immobilized thereon and then detecting the second ligand or label to indicate the presence of amplified DNA bound to said solid substrate.

29. The method according to claim 28 wherein the first and second set of oligonucleotide primers occur in a single reaction mixture.

30. The method according to claim 28 wherein the binding of the amplified DNA to the solid substance

occurs simultaneously to the binding of a detection complex.

31. The method according to claim 28 wherein the binding reagent is a DNA binding protein.

32. The method according to claim 31 wherein the DNA binding protein is a double stranded DNA-specific DNA binding sequence.

33. The method according to claim 32 wherein the double stranded DNA-specific DNA binding protein is of the leucine zipper type.

34. The method according to claim 33 wherein the binding protein is GCN4 and/or its derivatives.

35. The method according to claim 33 wherein the binding protein is GST-GCN4.

36. The method according to claim 32 wherein the double stranded DNA-specific DNA binding protein is of the helix turn helix type.

37. The method according to claim 36 wherein the binding protein is TyrR.

38. The method according to any one of claims 28 to 37 wherein the bound DNA is detected using a detection reagent comprising avidin/oxidase.

39. The method according to claim 38 wherein the binding moiety for the detection reagent is biotin.

40. The method according to claim 28 wherein the target DNA is HIV DNA.

41. The method according to any one of the preceding claims wherein the solid substance coated with the binding reagent is a well of a microtiter dish.

42. The method according to any one of the preceding claims wherein the solid substance coated with the binding reagent is a single or multiple bead or pin apparatus capable of transferring the amplified product with detection complex to a detection substrate.

43. A test kit for detecting target DNA in a sample by the amplified DNA assay comprising in compartmental form, a first container adapted to contain the reagents for an optional polymerase chain reaction and capable of receiving said target DNA including said first and/or optionally second sets of oligonucleotide primers; a second container adapted to contain said second set of oligonucleotide primers and the reagents for a second polymerase chain reaction when not carried in said first container; a solid substrate coated with a binding reagent; and a means for detecting amplified DNA bound to said solid substrate.

44. The test kit according to claim 43 wherein one primer of the second set is associated with a ligand recognized by the binding reagent.

45. The test kit according to claim 44 wherein the other primer of the second set is associated with a label.

46. The method according to any one of the preceding claims wherein the target DNA is cDNA copied by reverse transcriptase from RNA.

47. A conjugate consisting essentially of a support, GST-GSN4 immobilized on said support, and an amplified

49

double-stranded DNA bound at a first end to said GST-GCN4.

48. The conjugate according to claim 47 wherein at a second end the DNA is conjugated to a label.

49. The conjugate according to claim 48 wherein the label is an enzyme.

50. The conjugate according to claim 49 wherein the label is conjugated to the amplified DNA through an avidin-biotin bridge.

1/11




Fig.1.

2/11

Fig.2.





Fig.5.

3/11




Fig. 3.






Fig. 4.

4/11



a



b

Fig. 6.

5/11




Fig. 7.

6/11




Fig.8.

7/11

ADA DEPENDENCE ON TEMPERATURE SHIFT






Fig.9

8/11

Control cells	30 cycles
HIV + cells	95, 65
Plasmid	0.5, 1.0
Control cells	10 cycles
HIV + cells	95, 40, 65
Plasmid	0.5, 1.0, 0.5
Control cells	15 cycles
HIV + cells	
Plasmid	



.4	3	2	1	0	6	5	4	3	2	1	0
5X10:	5X10:	5X10:	5X10:	5X10:	5X10:	5X10:	5X10:	5X10:	5X10:	5X10:	5X10:
Cells	Cells	Cells	Cells	Cells	Cells	Cells	Cells	Cells	Cells	Cells	Cells

Fig. 10.

9/11




Fig.11.

10/11

COMPARISON OF TMB AND ABTS




Fig.12.


COMPARISON OF GCN4 AND TyrR IN AN ADA REACTION
T.TRIGLIA 11/9/89

Fig.13.

SUBSTITUTE SHEET

11/11




Fig.14.





Fig.15.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/AU 89/00526

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) 6		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl. ⁴ C12Q 1/68, G01N 33/543, 33/58, 33/571		
II. FIELDS SEARCHED		
Minimum Documentation Searched 7		
Classification System	Classification Symbols	
IPC	C12Q 1/68, G01N 33/543, 33/58, 33/571	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched 8		
AU : C12Q 1/68		
III. DOCUMENTS CONSIDERED TO BE RELEVANT 9		
Category*	Citation of Document, with indication, where appropriate, of the relevant passages 12	Relevant to Claim No 13
X	Nucleic Acids Research, vol.16, no.7, 11 April 1988, IRL Press (Oxford, GB), S. Stahl et al.: "Solid Phase DNA sequencing using the biotin-avidin system", pages 3025-3038, see whole article.	(1-50)
X	Nucleic Acids Research, vol.16, no.23, 1988, IRL Press (Oxford, GB), A. Syvanen et al.: "Quantification of polymerase chain reaction products by affinity-based hybrid collection", pages 11327-38, see whole article.	(1-50)
X	Chemical Abstracts, vol.109, no.19 issued 1988, November 7, (Columbus, Ohio, U.S.A.), A. Yamane et al., "Rapid detection of specific gene sequences". page 219, abstract no. 164992v & Nucleic Acids Symposium Ser. vol.20, 1988, A. Yamane et al., pages 91-92.	(1-50)
(continued)		
<p>* Special categories of cited documents: 10 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"8" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 22 March 1990 (22.03.90)	Date of Mailing of this International Search Report 5 April 1990	
International Searching Authority Australian Patent Office	Signature of Authorized Officer A.W. BESTOW 	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

X	EP,A, 223618 (NEW YORK MEDICAL COLLEGE) 27 May 1987 (27.05.87)	(1-50)
X	EP,A, 224126 (THE UNIVERSITY OF CALGARY) 3 June 1987 (03.06.87)	(1-50)
X	AU,A, 11937/88 (ORIAN-YHTYMA OY) 15 September 1988 (15.09.88)	(1-50)
P,X	EP,A, 329822 (CANGENE CORPORATION) 30 August 1989 (30.08.89)	(43-46)
P,X	EP,A, 297379 (MOLECULAR DIAGNOSTICS, INC.) 4 January 1989 (04.01.89)	(1-50)
P,X	WO 89/03891 (CHIRON CORPORATION) 5 May 1989 (05.05.89)	(1-50)
P,X	AU,A, 27359/88 (AMOCO CORPORATION) 13 July 1989 (13.07.89)	(1-50)
P,X	AU,A, 35622/89 (PAULSEN, G. et al.) 30 November 1989 (30.11.89)	(1-50)

V. [] OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [] Claim numbers ..., because they relate to subject matter not required to be searched by this Authority, namely:

◊

2. [] Claim numbers , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

◊

3. [] Claim numbers ..., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4 (a):

VI. [] OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 2

This International Searching Authority found multiple inventions in this international application as follows:

Claims 1-42, 44-46, claim 43, claims 47-50.

1. [] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. [] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. [] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. [X] As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

[] The additional search fees were accompanied by applicant's protest.

[] No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 89/00526

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Members			
EP	223618	JP 62085863	US	4863849	
EP	224126	JP 63219380			
AU	11937/88	DE 3807994	GB	2202328	JP 63243875
EP	329822	JP 2005864			
EP	297379	JP 1098499			
WO	8903891	DK 2945/89	EP	317077	WO 8903891
AU	27359/88	EP 328829	JP	1211500	
AU	35622/89	WO 8911546			

END OF ANNEX